Oruka Therapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Oruka Therapeutics, Inc. (ORKA) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $426.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-10
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $426.00K.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $299.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $359.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $421.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $426.00K 10-Q · filed 2026-08-10 |
| 2026-03-31 | $299.00K 10-Q · filed 2026-05-13 |
| 2025-12-31 | $359.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $421.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $492.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $233.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $275.00K 10-K · filed 2025-03-06 |
| 2024-09-30 | $318.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $1.00K 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.00K 10-Q · filed 2024-04-25 |
| 2023-12-31 | $34.00K 10-K · filed 2024-02-01 |
| 2023-09-30 | $39.00K 10-Q · filed 2023-10-18 |
| 2023-06-30 | $45.00K 10-Q · filed 2023-07-21 |
| 2023-03-31 | $51.00K 10-Q · filed 2023-04-24 |
| 2022-12-31 | $58.00K 10-K · filed 2023-02-24 |
| 2022-09-30 | $65.00K 10-Q · filed 2022-10-28 |
| 2022-06-30 | $72.00K 10-Q · filed 2022-08-02 |
| 2022-03-31 | $80.00K 10-Q · filed 2022-05-02 |
| 2021-12-31 | $89.00K 10-K · filed 2022-03-14 |
| 2021-09-30 | $97.00K 10-Q · filed 2021-11-02 |
| 2021-06-30 | $106.00K 10-Q · filed 2021-08-04 |
| 2021-03-31 | $106.00K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $113.00K 10-K · filed 2021-03-18 |
| 2019-10-10 | $34.00K 10-K · filed 2020-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |